LP
PMVP icon

Longaeva Partners’s PMV Pharmaceuticals PMVP Stock Holding History

Longaeva Partners’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-552,027
Closed -$685K – 391
2026
Q1 		$685K Buy
+552,027
New +$702K 0.03% 181

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Longaeva Partners's PMVP Position: Q2 2026 in Review

Longaeva Partners sold out of PMV Pharmaceuticals (PMVP) in Q2 2026, closing a stake of 552,027 shares — an estimated $685K sold.

Longaeva Partners first reported a position in PMVP in Q1 2026 and held it in 1 quarter. The position peaked at $685K in Q1 2026. 64 funds tracked by Wall St. Rank hold PMVP as of Q2 2026.

  • Longaeva Partners reported no remaining PMV Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Longaeva Partners sold 552,027 PMV Pharmaceuticals shares in Q2 2026, an estimated $685K.
  • Longaeva Partners first reported a position in PMV Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Longaeva Partners's PMV Pharmaceuticals position peaked at $685K in Q1 2026.
  • 64 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2026.

Based on Longaeva Partners's 13F filing for Q2 2026, filed 14 Aug 2026.